Freezing threatens mRNA delivery, but Tris buffer helps nanoparticles retain their potency
Researchers at The University of Texas at Austin have teamed up with pharmaceutical company Eli Lilly and Company to uncover how storage conditions affect mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other treatments, and how to make them more effective.
This is a short extract from a report by Phys.org. The full text stays with the publisher — follow the link to read it there.
Read at source